Novo Nordisk AS (NOVO B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company’s product portfolio includes new-generation insulins, modern insulins, human insulins, oral antidiabetic agents, diabetes devices and others. Novo Nordisk also offers biopharmaceuticals for treating haemostasis, human growth hormone products and hormone replacement therapy. With subsidiaries in Europe, North America, Asia, Latin America and Australia, it markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Novo Nordisk AS Key Recent Developments
Mar 01, 2017: Change in Novo Nordisk Executive Management
Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016
Jan 11, 2017: Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk A/S and Certain of its Senior Executives
Dec 20, 2016: Fluor to Design and Build $2 Billion Diabetes API Manufacturing Facility for Novo Nordisk in North Carolina
Nov 30, 2016: Ablynx Achieves First Milestone As Part Of Collaboration With Novo Nordisk
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Novo Nordisk A/S - Key Facts 6
Novo Nordisk A/S - Key Employees 7
Novo Nordisk A/S - Key Employee Biographies 8
Novo Nordisk A/S - Major Products and Services 9
Novo Nordisk A/S - Pharmaceutical Pipeline Products Data 11
Novo Nordisk A/S, Pipeline Products by Therapy Area 11
Novo Nordisk A/S, Pipeline Products by Development Phase 12
Novo Nordisk A/S - History 13
Novo Nordisk A/S - Company Statement 21
Novo Nordisk A/S - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Section 2 – Company Analysis 29
Novo Nordisk A/S - Business Description 29
Novo Nordisk A/S - Corporate Strategy 30
Novo Nordisk A/S - SWOT Analysis 31
SWOT Analysis - Overview 31
Novo Nordisk A/S - Strengths 31
Novo Nordisk A/S - Weaknesses 32
Novo Nordisk A/S - Opportunities 33
Novo Nordisk A/S - Threats 34
Novo Nordisk A/S - Key Competitors 35
Section 3 – Company Financial Ratios 36
Financial Ratios - Capital Market Ratios 36
Financial Ratios - Annual Ratios 37
Performance Chart 39
Financial Performance 39
Financial Ratios - Interim Ratios 40
Financial Ratios - Ratio Charts 41
Section 4 – Company’s Lifesciences Financial Deals and Alliances 42
Novo Nordisk A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 42
Novo Nordisk A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 43
Novo Nordisk A/S, Recent Deals Summary 44
Section 5 – Company’s Recent Developments 45
Mar 01, 2017: Change in Novo Nordisk Executive Management 45
Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016 46
Jan 11, 2017: Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk A/S and Certain of its Senior Executives 47
Dec 20, 2016: Fluor to Design and Build $2 Billion Diabetes API Manufacturing Facility for Novo Nordisk in North Carolina 48
Nov 30, 2016: Ablynx Achieves First Milestone As Part Of Collaboration With Novo Nordisk 49
Nov 14, 2016: Novo Nordisk expands programme to reach 20,000 children with diabetes in developing countries 50
Nov 03, 2016: New study showed that only 55% of people with obesity have received a formal obesity diagnosis 51
Nov 01, 2016: New data show post-meal hyperglycaemia is associated with a negative impact on quality of life for people with diabetes 52
Oct 28, 2016: Novo Nordisk increased adjusted operating profit by 7% in local currencies in the first nine months of 2016 53
Sep 29, 2016: Novo Nordisk announces plans to reduce workforce by approximately 1,000 employees 54
Section 6 – Appendix 55
Methodology 55
Ratio Definitions 55
About GlobalData 59
Contact Us 59
Disclaimer 59
List of Tables
Novo Nordisk A/S, Key Facts 6
Novo Nordisk A/S, Key Employees 7
Novo Nordisk A/S, Key Employee Biographies 8
Novo Nordisk A/S, Major Products and Services 9
Novo Nordisk A/S, Number of Pipeline Products by Therapy Area 11
Novo Nordisk A/S, Number of Pipeline Products by Development Stage 12
Novo Nordisk A/S, History 13
Novo Nordisk A/S, Subsidiaries 23
Novo Nordisk A/S, Key Competitors 35
Novo Nordisk A/S, Ratios based on current share price 36
Novo Nordisk A/S, Annual Ratios 37
Novo Nordisk A/S (Cont...1), Annual Ratios 38
Novo Nordisk A/S, Interim Ratios 40
Novo Nordisk A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 42
Novo Nordisk A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 43
Novo Nordisk A/S, Recent Deals Summary 44
Currency Codes 55
Capital Market Ratios 55
Equity Ratios 56
Profitability Ratios 56
Cost Ratios 57
Liquidity Ratios 57
Leverage Ratios 57
Efficiency Ratios 58
List of Figures
Novo Nordisk A/S, Pipeline Products by Therapy Area 11
Novo Nordisk A/S, Pipeline Products by Development Phase 12
Novo Nordisk A/S, Performance Chart (2012 - 2016) 39
Novo Nordisk A/S, Ratio Charts 41
Novo Nordisk A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 42
Novo Nordisk A/S, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 43
